AKBA up +8.68% percent right now. $AKBA High is at 9.88 and

New Post Public Reply Private Reply Replies (0) Message Board

Nov 11, 2014 at 3:08 PM

AKBA up +8.68% percent right now. $AKBA High is at 9.88 and the Low 9.32 with current volume of 147,944.

Recent News posted below.

AKBA Akebia Therapeutics Inc. Recent Headline News

Akebia Announces Poster Presentations at the Upcoming American Society of Nephrology Kidney Week 2014 Annual Meeting
Business Wire - Tue Nov 11, 6:00AM CST
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that data from the AKB-6548 development program will be presented in two poster sessions at the upcoming American Society of Nephrology (ASN) Kidney Week 2014 annual meeting in Philadelphia, PA from November 11-16, 2014.
AKBA: 10.10 (+1.11)

Nasdaq stocks posting largest percentage decreases
AP - Mon Nov 10, 5:07PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
HYGS: 14.92 (-1.04), KNDI: 15.45 (+0.59), PAAS: 9.74 (+0.57), PAA.TO: 11.01 (+0.57), RPRX: 9.70 (+0.48), REXX: 7.65 (+0.42), HYG.TO: 16.92 (-1.25), AKBA: 10.10 (+1.11), MTEX: 19.55 (-0.22), SHLD: 37.03 (-1.69)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 11:59AM CST

UCP: 11.63 (-0.26), JRJC: 7.46 (+1.02), NAVB: 1.00 (-0.03), SANW: 3.65 (+0.01), PLPM: 1.74 (+0.07), RYN: 26.59 (-2.23), INFU: 2.91 (-0.06), LIOX: 5.41 (-0.13), DY: 28.14 (+0.17), MTZ: 24.83 (-0.10), CGIX: 6.52 (-0.16), MUX: 1.40 (+0.17), OREX: 5.04 (-0.09), URRE: 2.45 (-0.11), ACHN: 12.41 (-0.44), REN: 2.71 (-0.19), MPO: 3.14 (-0.07), AKBA: 10.10 (+1.11), TRX: 1.16 (+0.12), PLNR: 6.65 (-1.03)

Akebia misses by $0.02
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:20AM CST

AKBA: 10.10 (+1.11)

Akebia Announces Third Quarter 2014 Financial Results
Business Wire - Mon Nov 10, 6:00AM CST
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced financial results for the third quarter ended September 30, 2014.
AKBA: 10.10 (+1.11)

Akebia to Participate in Upcoming Investor Conferences
Business Wire - Fri Oct 31, 6:00AM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that John P. Butler, President and Chief Executive Officer, will participate in two upcoming investor conferences:
AKBA: 10.10 (+1.11)

Akebia getting roughed up
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 2:55PM CDT

AKBA: 10.10 (+1.11)

Akebia renal anemia drug successful in Phase 2
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 6:13AM CDT

AKBA: 10.10 (+1.11)

Akebia Announces Positive Top-Line Results from its Phase 2b Study of AKB-6548 in Non-Dialysis Patients with Anemia Related to Chronic Kidney Disease
Business Wire - Mon Oct 27, 5:30AM CDT
--Company Plans to Initiate Global Phase 3 Registration Studies in 2015
AKBA: 10.10 (+1.11)

Akebia Announces Dosing of First Patient in Phase 2 Study of AKB-6548 in Patients with Anemia Related to Chronic Kidney Disease Undergoing Dialysis
Business Wire - Thu Sep 25, 6:00AM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development of novel, proprietary therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease, today announced that the first patient has been dosed in a Phase 2 clinical study of AKB-6548 in patients with anemia related to chronic kidney disease (CKD) who are undergoing dialysis. AKB-6548 is being developed as a once-daily, oral therapy with best-in-class potential for the treatment of anemia related to CKD.
AKBA: 10.10 (+1.11)

Concert Pharmaceuticals (CNCE) Soars: Stock Rises 25.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 7:57AM CDT
Concert Pharmaceuticals, Inc. (CNCE) was a big mover last session, as the company saw its shares rise nearly 26% on the day.
LCI: 50.19 (-1.62), AKBA: 10.10 (+1.11), CNCE: 13.20 (-0.17), HPTX: 21.70 (+0.12)

Others Overlooked Akebia Therapeutics (AKBA), Should You Buy It Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 7:45AM CDT
Akebia Therapeutics has been witnessing a positive trend in its current year estimates and possess a favorable Zacks Rank #2(Buy)
AKBA: 10.10 (+1.11)

Akebia Therapeutics Appoints Ronald C. Renaud Jr. to its Board of Directors
Business Wire - Mon Sep 15, 6:15AM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development of novel, proprietary therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease, today announced that Ronald C. Renaud, Jr., former President, Chief Executive Officer and Director of Idenix Pharmaceuticals, Inc., has been appointed to Akebia's Board of Directors.
AKBA: 10.10 (+1.11), IDIX: 24.50 (+0.05)

Akebia Therapeutics, Inc. (NASDAQ: AKBA) to Ring The NASDAQ Stock Market Opening Bell
GlobeNewswire - Thu Sep 11, 9:06AM CDT
What:
AKBA: 10.10 (+1.11), NDAQ: 44.14 (+0.11)

Can the Uptrend Continue for Akebia (AKBA)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 8:33AM CDT
Can the Uptrend Continue for Akebia (AKBA)?
AKBA: 10.10 (+1.11)

Akebia Announces Second Quarter 2014 Financial Results
Business Wire - Mon Aug 11, 6:00AM CDT
---Strengthens Management Team and Board-
AKBA: 10.10 (+1.11)

Akebia Therapeutics Announces Expansion of Management Team
Business Wire - Wed Aug 06, 6:00AM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on harnessing the potential of hypoxia-inducible factor (HIF) biology to develop and commercialize novel therapeutics to treat kidney disease, today announced the expansion of its senior management team with three key additions: Brad Maroni, M.D., as Senior Vice President and Chief Medical Officer, Mark De Rosch, Ph.D., as Vice President of Regulatory Affairs and Tamara Dillon as Vice President of Human Resources.
AKBA: 10.10 (+1.11)

Akebia Therapeutics Appoints Michael Clayman, M.D. and Maxine Gowen, Ph.D. to its Board of Directors
Business Wire - Thu Jul 17, 6:00AM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on harnessing the potential of hypoxia-inducible factor (HIF) biology to develop and commercialize novel therapeutics to treat kidney disease, today announced that Michael D. Clayman, M.D., Chief Executive Officer of Flexion Therapeutics, Inc., and Maxine Gowen, Ph.D., President and Chief Executive Officer of Trevena, Inc., have been appointed to the Company's Board of Directors. In addition, Kim L. Dueholm, Ph.D. will be stepping down from the Board on July 28, 2014, the effective date of Dr. Clayman and Dr. Gowen's appointments.
TRVN: 5.64 (-0.21), FLXN: 18.88 (+0.01), AKBA: 10.10 (+1.11)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Summit Tackles BRI Infrastructure's Role in Global SDGs

A Bold Gathering with Lofty Goals Ever watch a room of world leaders debate the finer nuances of sustainable infrastructure? That's something Singapore pulled off on September 6, 2026, with the Second Global Business Summit on Belt and Road Infrastructure Investment. These aren't just any ordinary suits sitting around in a conference room. We're talking about a dynamic...

Hims & Hers Faces Class Action: Investors Beware

Allegations and Legal Pressure There's trouble brewing in the land of health and wellness apps, with Hims & Hers Health, Inc. (NYSE:HIMS) taking center stage. Slap on your glasses, folks, because this one's a doozy. A class-action lawsuit has exploded against the company and some of its officers—allegations flying as they focus on serious accusations of misleading...

EyePoint Stumbles: Legal Eagles Circle Post-Trial Flop

EyePoint Slips on Clinical Banana Peel Well, if EyePoint was aiming for a splash, they sure got it—just not the kind they were hoping for. News dropped like a lead balloon when EyePoint announced their Phase 3 DURAVYU trial results for wet age-related macular degeneration, revealing they missed their primary endpoint. And what did that mean for their stock? A death...

Changhong's IFA 2026 Showcase: AI, Culture & Localization

Changhong's Game Plan: From Global Reach to Local Touch Well, Changhong's not sitting back at IFA 2026, let me tell you that. This isn't your run-of-the-mill showcase; it's a full-on reveal of what happens when a company takes AI tech and tunes it to the heartbeat of daily life. TVs, fridges, air conditioners—you name it, they've got an AI twist on it. But is this just...

FDI Launches 'Generation Smile' for Global Oral Health

A New Kind of Movement Imagine a campaign not bound by age or geography but united by a shared mission. Generation Smile, freshly launched by the FDI World Dental Federation in Prague, is just that kind of uprising. This initiative redefines existing approaches to oral health, pushing beyond the boundaries of mere dental care to emphasize the integral role oral health...

Pudu D7 Robot Shines at IFA, Setting New Robotics Bar

Breaking New Ground in Robotics at IFA Well, here's a nugget for robotics buffs and investors alike: Pudu Robotics, a heavyweight in commercial service robotics, is carving out a fresh chapter with its PUDU D7. Making waves as an honoree at the IFA Innovation Awards, the D7 presents a mash-up of brains and brawn—exemplifying the future path for robotics. The PUDU D7...

DUVA ONE Sleep Earbuds: Real-Time Innovation Debuts

While You Dream, DUVA ONE Works Here's the scoop: DUVA just took sleep tech to another level with their DUVA ONE earbuds launched at Berlin's IFA 2026. These aren't just any earbuds; they're engineered to actually do something while you're sleeping. DUVA ONE senses what’s happening during your snooze session and adjusts right on the fly. The Night Patrol: In-Ear and...

ATTACK SHARK Partners with Cloud9 League Team

Shaking Hands with Cloud9 ATTACK SHARK is jumping headfirst into the esports game, teaming up with Cloud9's League of Legends team. Now, before you roll your eyes at another corporate matchmaking play, consider the magic at play here. League of Legends isn't just any game; it's a titan in the esports universe, and partnering with Cloud9 offers a serious boost. It's not...

China's Manufacturing: Squeeze or Opportunity?

Analyzing China's Impact on Global Markets Think of China's manufacturing clout and you're likely to picture booming factories, relentless steel, and smoke-churning industries reshaping the global chessboard. But here's the kicker: are they swallowing up room for others, or paving the way for their growth? It’s this debate that took the spotlight at the Asia-Pacific...

TCL’s AI Vision: Immersive Living at IFA 2026

AI and Displays: A Match Made in Tech Heaven Every so often, a company stands up at a tech fair and gives a glimpse into the next chapter of living, as TCL did at IFA 2026. This time, they're not just talking about screens; they're weaving them into the fabric of everyday life alongside AI capabilities. From sporting arenas to your living room, it's a vision of what could...